Home › Research › TREM2 and immune genetics
Immunosuppressive TREM2(+) macrophages are associated with undesirable prognosis and responses to anti-PD-1 immunotherapy in non-small cell lung cancer
Zhang H, Liu Z, Wen H, Guo Y, Xu F, Zhu Q, Yuan W, Luo R et al.. Cancer immunology, immunotherapy : CII, 2022-03-12
Topic: Brain proteins, microglia and lab models
Background Immune checkpoint blockade (ICB) has been improving patient outcomes of non-small cell lung cancer (NSCLC), but its effectiveness is highly subjective to individual tumor microenvironment. As dominant immune cells in NSCLC, tumor-associated macrophages (TAMs) display high diversity and plasticity. This study aims to find crucial TAM subtypes associated with ICB response in NSCLC.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Zhang, H., Liu, Z., Wen, H., Guo, Y., Xu, F., Zhu, Q., et al. (2022). Immunosuppressive TREM2(+) macrophages are associated with undesirable prognosis and responses to anti-PD-1 immunotherapy in non-small cell lung cancer. Cancer immunology, immunotherapy : CII. https://doi.org/10.1007/s00262-022-03173-w
Vancouver
Zhang H, Liu Z, Wen H, Guo Y, Xu F, Zhu Q, et al. Immunosuppressive TREM2(+) macrophages are associated with undesirable prognosis and responses to anti-PD-1 immunotherapy in non-small cell lung cancer. Cancer immunology, immunotherapy : CII. 2022. doi:10.1007/s00262-022-03173-w. PMID: 35278107.
BibTeX
@article{zhang2022-35278107,
author = {Zhang, H. and Liu, Z. and Wen, H. and Guo, Y. and Xu, F. and Zhu, Q. and Yuan, W. and Luo, R. and others},
title = {{Immunosuppressive TREM2(+) macrophages are associated with undesirable prognosis and responses to anti-PD-1 immunotherapy in non-small cell lung cancer}},
journal = {Cancer immunology, immunotherapy : CII},
year = {2022},
doi = {10.1007/s00262-022-03173-w},
pmid = {35278107},
url = {https://doi.org/10.1007/s00262-022-03173-w}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- As dominant immune cells in NSCLC, tumor-associated macrophages (TAMs) display high diversity and plasticity.
- This study aims to find crucial TAM subtypes associated with ICB response in NSCLC.
- Materials and methods Large cohorts of NSCLC patients from The Cancer Genome Atlas and a single-cell sequencing dataset were integrated to illustrate immunosuppressive phenotypes of TAMs, followed by experimental verification. 341 NSCLC surgical samples and 40 tissue samples of NSCLC patients who received ICB treatment were collected to state the clinical importance of TAMs.
- Results We identified a TREM2 positive ( + ) TAM subtype in NSCLC stratifying patient responses to immunotherapy.
Why it matters
This study is about non-small cell lung cancer and found that immunosuppressive TREM2-positive macrophages were linked to worse prognosis and poorer responses to anti-PD-1 immunotherapy. It has no relevance to treating, curing, or preventing Alzheimer's disease.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Effect size31.58%; 14.29%
- Evidence strengthLow
How this study scored 46/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Cancer immunology, immunotherapy : CII) |
| Journal's citation record | 2 / 4 | Cancer Immunology Immunotherapy: journal h-index 164 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 112 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 18.7 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 3 / 6 | Cited 6.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 5 other studies in this library |
| Still being cited | 3 / 4 | Cited 76 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Di Ge: h-index 14 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Fudan University: institution h-index 954 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 35278107) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 46 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
5 studies in the alzhub library list this one in their references.
Related studies in TREM2 and immune genetics
Also tagged “macrophages”
363 studies in the library carry the topic tag “macrophages”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 363 tagged studies.